Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Insulet Corporation - Common Stock (NQ: PODD )

259.38 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase... 
Via Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
Expert Ratings For Insulet
Analysts have provided the following ratings for Insulet (NASDAQ:PODD) within the last quarter: 
Via Benzinga
Earnings Scheduled For February 23, 2022
Companies Reporting Before The Bell • Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter. • Plymouth Industrial REIT (NYSE:PLYM)... 
Via Benzinga
Insulet Promotes Inclusivity for People with Diabetes through Nintendo® Video Game Animal Crossing™: New Horizons
From Insulet Corporation
Via Business Wire
Insulet to Present at Upcoming Investor Conferences
From Insulet Corporation
Via Business Wire
Insulet Announces Board Appointment of Elizabeth Weatherman and Retirement of David Lemoine
From Insulet Corporation
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2022
Upgrades BTIG upgraded the previous rating for Insulet Corp (NASDAQ:PODD) from Neutral to Buy. For the third quarter, Insulet had an EPS of $0.18, compared to year-ago... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Provention Bio (NASDAQ:PRVB) stoc... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 2, 2022
Upgrades Oppenheimer upgraded the previous rating for NovoCure Ltd (NASDAQ:NVCR) from Perform to Outperform. NovoCure earned $0.13 in the third quarter, compared to $0.09... 
Via Benzinga
FDA Approves Insulet's Omnipod Automated Insulin Delivery System Patients Aged 6 Years & Above
The 
Via Benzinga
Mid-Day Market Update: US Stocks Turn Positive; Nasdaq Surges 2%
US stocks turned higher, with all the three major indices recording gains. The Nasdaq climbed more than 2% following stronger-than-expected earnings results from Apple Inc. (... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 31, 2022
Upgrades UBS upgraded the previous rating for Align Technology Inc (NASDAQ:ALGN) from Neutral to Buy. For the third quarter, Align Tech had an EPS of $2.87, compared to year-ago... 
Via Benzinga
33 Stocks Moving In Friday's Mid-Day Session
Gainers Imperial Petroleum Inc. (NASDAQ: IMPP) shares jumped 126% to $2.6219. Imperial Petroleum, last month, posted Q3 revenue of $4.1 million. Yoshitsu Co., Ltd (NASDAQ: TKLF... 
Via Benzinga
52 Biggest Movers From Friday
Gainers Knightscope, Inc. (NASDAQ: KSCP) surged 175.6% to close at $3.40 on Friday. The company, on Thursday, priced its IPO at $10 per share. Imperial Petroleum Inc. (NASDAQ:... 
Via Benzinga
Benzinga Pro's Top 5 Stocks To Watch For Friday, Jan. 28, 2022: PODD, KR, TEAM, GOOGL, SBUX
Today's 5 Stock Ideas: Insulet (PODD) - Shares up premarket. The company announced FDA clearance of its Omnipod 5 Automated Insulin Delivery System. Kroger (KR) - Shares... 
Via Benzinga
Insulet Announces FDA Clearance of its Omnipod® 5 Automated Insulin Delivery System, First Tubeless System with Smartphone Control
From Insulet Corporation
Via Business Wire
If You Invested $100 In This Stock 5 Years Ago, Here's How Much You Would Have Today
Insulet (NASDAQ:PODD) has outperformed the market over the past 5 years by 24.86% on an annualized basis. Buying $100 In PODD: 5 years ago, an investor could have purchased 2.30... 
Via Benzinga
This Foreboding Sign Looms Over Insulet's Chart
If history is any guide, there may be trouble ahead for shares of Insulet (NASDAQ:PODD). A so-called "death cross" has formed on its chart and, not surprisingly, this could be... 
Via Benzinga
CORRECTING and REPLACING Insulet to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
From Insulet Corporation
Via Business Wire
Insulet to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2021
From Insulet Corporation
Via Business Wire
Insulet to Present at Nasdaq’s 45th Investor Conference
From Insulet Corporation
Via Business Wire
10 Biggest Price Target Changes For Monday
Barclays cut Deciphera Pharmaceuticals, Inc. (NASDAQ: 
Via Benzinga
10 Biggest Price Target Changes For Friday
Wedbush raised Uber Technologies, Inc. (NYSE:UBER)... 
Via Benzinga
Insulet Corporation (PODD) Q3 2021 Earnings Call Transcript
PODD earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Insulet Posts Mixed Third Quarter, But Raises Sales Guide On Narrow Beat
Insulet raised its full-year sales outlook Thursday on its third-quarter sales beat. 
Via Investor's Business Daily
Insulet Reports Third Quarter 2021 Revenue Increase of 18% Year-Over-Year
From Insulet Corporation
Via Business Wire
Insulet Honors Diabetes Awareness with Global Activities and Events
From Insulet Corporation
Via Business Wire
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Exposures COVID-19
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.